Pub Date : 2018-09-25DOI: 10.17554/J.ISSN.2309-6861.2018.05.159
G. Caminiti, R. Massaro, C. Fossati, L. Gatta, S. Selli, M. Volterrani
Ranolazine (R) is a non-haemodynamic anti-anginal agent used as adjunctive therapy in patients with chronic coronary heart disease (CHD) whose symptoms are unadequately controlled by conventional treatment. R decreases calcium overload in the ischemic myocytes through the inhibition of late sodium channel current in the myocardium; induces myocardial relaxation and improves myocardial blood flow. In addition to its anti-angina effect, other possible clinical applications of R have also been explored, including treatment of atrial arrhythmias, chronic heart failure and diabetes. With regard to diabetes R has been shown to significantly improve glycemic control in diabetic patients with CHD in post-hoc analysis of large-scale clinical trials. Moreover reduction of glycated hemoglobin and fasting serum glucose levels have been also observed prospectively in small clinical trials conducted on diabetic subjects without CHD by using R alone or in combination with other oral glucose-lowering drugs. Lastly R improved insulin resistance in non-diabetic overweight/obese patients with CHD. Hypothetical mechanisms of this metabolic action are: inhibition of secretion of glucagon from pancreatic islets, preservation of beta cells and increase of insulin delivery to tissues. In light of these observations R appear to be a potential multifaceted drug that offers the opportunity to treat glyco-metabolic disorders alone or in association to CHD. However, prospective studies are too small to be conclusive and new trials are needed to clarify which is the exact role of R in the treatment of glyco-metabolic disorders.
{"title":"Glyco-metabolic effects of ranolazine. A truly multifaceted drug?","authors":"G. Caminiti, R. Massaro, C. Fossati, L. Gatta, S. Selli, M. Volterrani","doi":"10.17554/J.ISSN.2309-6861.2018.05.159","DOIUrl":"https://doi.org/10.17554/J.ISSN.2309-6861.2018.05.159","url":null,"abstract":"Ranolazine (R) is a non-haemodynamic anti-anginal agent used as adjunctive therapy in patients with chronic coronary heart disease (CHD) whose symptoms are unadequately controlled by conventional treatment. R decreases calcium overload in the ischemic myocytes through the inhibition of late sodium channel current in the myocardium; induces myocardial relaxation and improves myocardial blood flow. In addition to its anti-angina effect, other possible clinical applications of R have also been explored, including treatment of atrial arrhythmias, chronic heart failure and diabetes. With regard to diabetes R has been shown to significantly improve glycemic control in diabetic patients with CHD in post-hoc analysis of large-scale clinical trials. Moreover reduction of glycated hemoglobin and fasting serum glucose levels have been also observed prospectively in small clinical trials conducted on diabetic subjects without CHD by using R alone or in combination with other oral glucose-lowering drugs. Lastly R improved insulin resistance in non-diabetic overweight/obese patients with CHD. Hypothetical mechanisms of this metabolic action are: inhibition of secretion of glucagon from pancreatic islets, preservation of beta cells and increase of insulin delivery to tissues. In light of these observations R appear to be a potential multifaceted drug that offers the opportunity to treat glyco-metabolic disorders alone or in association to CHD. However, prospective studies are too small to be conclusive and new trials are needed to clarify which is the exact role of R in the treatment of glyco-metabolic disorders.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"30 1 1","pages":"742-746"},"PeriodicalIF":0.0,"publicationDate":"2018-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90053396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-12DOI: 10.17554/J.ISSN.2309-6861.2018.05.155
S. Marconcini, E. Giammarinaro, S. Cosola, Chiara Giampietro, A. Genovesi, U. Covani, O. Giampietro
Introduction: Bruxism is a parafunctional activity with unclear etiology. Psychological stress might be involved. The aim of this observational study was to compare the prevalence of bruxism between cardiopathic patients and non-cardiopathic patients. Subjects and methods: The population study was based on 120 patients divided in 2 groups: Cardiopathic patients (Test-group; n=60) and Non-Cardiopathic patients (Control-group; n=60). All the patients included in the study were screened for bruxism with the “tooth wear Index” (TWI). The TWI value was supposed to be higher or equal to 2 for the 50% of the teeth to define the diagnosis of bruxism. The prevalence of bruxism was calculated and compared in both groups. Results: In the Test-group, 55 out of 60 cardiopathic patients were bruxist, with a prevalence of 91,67%. In the Control-group, 17 out of 60 non cardiopathic patients were bruxist with a prevalence of 28,33%. (Table-3) Conclusion: Cardiopathic patients showed a higher prevalence of bruxism than non-cardiopathic patients. Further prospective studies are needed to evaluate the relation occurring between the two conditions.
{"title":"Bruxism and Cardio Vascular Diseases: a cross-sectional study","authors":"S. Marconcini, E. Giammarinaro, S. Cosola, Chiara Giampietro, A. Genovesi, U. Covani, O. Giampietro","doi":"10.17554/J.ISSN.2309-6861.2018.05.155","DOIUrl":"https://doi.org/10.17554/J.ISSN.2309-6861.2018.05.155","url":null,"abstract":"Introduction: Bruxism is a parafunctional activity with unclear etiology. Psychological stress might be involved. The aim of this observational study was to compare the prevalence of bruxism between cardiopathic patients and non-cardiopathic patients. Subjects and methods: The population study was based on 120 patients divided in 2 groups: Cardiopathic patients (Test-group; n=60) and Non-Cardiopathic patients (Control-group; n=60). All the patients included in the study were screened for bruxism with the “tooth wear Index” (TWI). The TWI value was supposed to be higher or equal to 2 for the 50% of the teeth to define the diagnosis of bruxism. The prevalence of bruxism was calculated and compared in both groups. Results: In the Test-group, 55 out of 60 cardiopathic patients were bruxist, with a prevalence of 91,67%. In the Control-group, 17 out of 60 non cardiopathic patients were bruxist with a prevalence of 28,33%. (Table-3) Conclusion: Cardiopathic patients showed a higher prevalence of bruxism than non-cardiopathic patients. Further prospective studies are needed to evaluate the relation occurring between the two conditions.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"62 1","pages":"734-737"},"PeriodicalIF":0.0,"publicationDate":"2018-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81072349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-12DOI: 10.17554/J.ISSN.2309-6861.2018.05.150
A. Taksande
Background: Diabetes in pregnancy is associated with an increased risk of complications in both the mother and fetus. Transient cardiac hypertrophy occurs in infants of diabetic mothers. Thus the aim of this study was to determine the changes in left ventricular function by Tissue Doppler echocardiography in an infants of diabetic mothers. Material and Methods: This was a case controlled study comprised of 15infant of diabetic mothers ( cases ) and 15 healthy term babies (controls ). M-mode, Two-Dimensional, Doppler and Tissue Doppler Imaging measurements of cases and controls were performed. Results: There were 09 males and 06 females in the cases group. Both the left and right ventricle myocardial velocities were found to be lower in the infant of diabetic mothers compared to the control group. The E ’ /A ’ ratio was found to be less than one in the left ventricle, right ventricular and septum in cases as compare to control group. The Tei index was found to be higher in the infant of diabetic mothers who had a thicker interventricular septum compared to the control group. Conclusions: Tissue Doppler echocardiographyis a useful, sensitive, non-invasive technique to study the changes in myocardial structure and function. The systolic and diastolic function indices measures are affected in babies of diabetic mothers as compare to normal neonates but not statistically significant.
{"title":"Tissue Doppler Echocardiography: Assessment of the Cardiac functions in an infants of diabetic mothers","authors":"A. Taksande","doi":"10.17554/J.ISSN.2309-6861.2018.05.150","DOIUrl":"https://doi.org/10.17554/J.ISSN.2309-6861.2018.05.150","url":null,"abstract":"Background: Diabetes in pregnancy is associated with an increased risk of complications in both the mother and fetus. Transient cardiac hypertrophy occurs in infants of diabetic mothers. Thus the aim of this study was to determine the changes in left ventricular function by Tissue Doppler echocardiography in an infants of diabetic mothers. Material and Methods: This was a case controlled study comprised of 15infant of diabetic mothers ( cases ) and 15 healthy term babies (controls ). M-mode, Two-Dimensional, Doppler and Tissue Doppler Imaging measurements of cases and controls were performed. Results: There were 09 males and 06 females in the cases group. Both the left and right ventricle myocardial velocities were found to be lower in the infant of diabetic mothers compared to the control group. The E ’ /A ’ ratio was found to be less than one in the left ventricle, right ventricular and septum in cases as compare to control group. The Tei index was found to be higher in the infant of diabetic mothers who had a thicker interventricular septum compared to the control group. Conclusions: Tissue Doppler echocardiographyis a useful, sensitive, non-invasive technique to study the changes in myocardial structure and function. The systolic and diastolic function indices measures are affected in babies of diabetic mothers as compare to normal neonates but not statistically significant.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"70 1","pages":"738-741"},"PeriodicalIF":0.0,"publicationDate":"2018-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84229303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-06-24DOI: 10.17554/J.ISSN.2309-6861.2018.05.148
D. Chua, S. Tkachuk
BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) are commonly used for stroke prophylaxis in patients with atrial fibrillation (AF), but their efficacy and safety in patients with underlying valvular heart disease (VHD) is unknown. METHODS: A search of MEDLINE, CENTRAL, Embase, clinicaltrials.gov was performed with the terms direct oral antiocoagulants, new oral anticoagulants, DOAC, NOAC, rivaroxaban, apixaban, dabigatran, valvular heart disease, aortic stenosis, aortic regurgitation, mitral regurgitation, tricuspid stenosis, tricuspid regurgitation, pulmonary stenosis and pulmonary regurgitation. Only clinical studies with clinical endpoints that compared NOACs with warfarin in patients with AF and identified VHD were included. RESULTS: Four clinical studies were retrieved based on our search criteria. Subgroup analysis of the landmark trials comparing a NOAC to warfarin in AF patients with underlying VHD demonstrated that NOACs had similar or superior efficacy in stroke prevention compared to warfarin. The risk of bleeding with NOACs compared to warfarin in these patients yielded inconsistent results. CONCLUSION: Based on the available evidence, NOACs provide similar or superior stroke reduction compared to warfarin in patients with AF and VHD, especially in aortic valve disease and mitral regurgitation. The rate of major bleeding between NOACs and warfarin in this patient population is unclear.
{"title":"Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) for Stroke Prevention in Atrial Fibrillation and Valvular Heart Disease – Systematic Review","authors":"D. Chua, S. Tkachuk","doi":"10.17554/J.ISSN.2309-6861.2018.05.148","DOIUrl":"https://doi.org/10.17554/J.ISSN.2309-6861.2018.05.148","url":null,"abstract":"BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) are commonly used for stroke prophylaxis in patients with atrial fibrillation (AF), but their efficacy and safety in patients with underlying valvular heart disease (VHD) is unknown. METHODS: A search of MEDLINE, CENTRAL, Embase, clinicaltrials.gov was performed with the terms direct oral antiocoagulants, new oral anticoagulants, DOAC, NOAC, rivaroxaban, apixaban, dabigatran, valvular heart disease, aortic stenosis, aortic regurgitation, mitral regurgitation, tricuspid stenosis, tricuspid regurgitation, pulmonary stenosis and pulmonary regurgitation. Only clinical studies with clinical endpoints that compared NOACs with warfarin in patients with AF and identified VHD were included. RESULTS: Four clinical studies were retrieved based on our search criteria. Subgroup analysis of the landmark trials comparing a NOAC to warfarin in AF patients with underlying VHD demonstrated that NOACs had similar or superior efficacy in stroke prevention compared to warfarin. The risk of bleeding with NOACs compared to warfarin in these patients yielded inconsistent results. CONCLUSION: Based on the available evidence, NOACs provide similar or superior stroke reduction compared to warfarin in patients with AF and VHD, especially in aortic valve disease and mitral regurgitation. The rate of major bleeding between NOACs and warfarin in this patient population is unclear.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"14 1","pages":"729-733"},"PeriodicalIF":0.0,"publicationDate":"2018-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86042797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-05-02DOI: 10.17554/J.ISSN.2309-6861.2018.05.147
Qianyun Wu, I. Cheang, Xinli Li
Restrictive Cardiomyopathy (RCM) is a form of cardiomyopathy, which having improper blood filling by different restricted etiologies. RCM can be clinically challenging and often result of a poor prognosis. With the early and precise medical intervention, expectancy outcomes are better. In this article, we review an updated of restrictive cardiomyopathy which are published and provide an overview diagnosis and treatment advancement of the disease.
{"title":"Precise Medicine of Restrictive Cardiomyopathy","authors":"Qianyun Wu, I. Cheang, Xinli Li","doi":"10.17554/J.ISSN.2309-6861.2018.05.147","DOIUrl":"https://doi.org/10.17554/J.ISSN.2309-6861.2018.05.147","url":null,"abstract":"Restrictive Cardiomyopathy (RCM) is a form of cardiomyopathy, which having improper blood filling by different restricted etiologies. RCM can be clinically challenging and often result of a poor prognosis. With the early and precise medical intervention, expectancy outcomes are better. In this article, we review an updated of restrictive cardiomyopathy which are published and provide an overview diagnosis and treatment advancement of the disease.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"27 1","pages":"723-728"},"PeriodicalIF":0.0,"publicationDate":"2018-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72675694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-03-19DOI: 10.17554/J.ISSN.2309-6861.2018.05.142
S. Partridge, J. Redfern
Cardiovascular disease (CVD) is the leading cause of death worldwide. Excess weight gain during adolescence (14-18 years) and young adulthood (18-24 years) is associated with CVD in later life. Despite the significant investment into treatment for obesity, efforts have had limited success. Aiming to prevent obesity by halting weight gains at critical life stages where weight gain occurs, such as adolescence and young adulthood, could be a solution towards combating the obesity epidemic and thus reducing CVD prevalence in later life. Technology-based interventions can improve lifestyle behaviours in adults. Currently, over 80% of young people in developed countries own a Smartphone. Smartphones may offer an opportunity for intervention. However, there is limited long-term evidence for the role of mhealth in primary prevention of CVD in young people. In this manuscript, we discuss and review the potential use of mhealth for the primary prevention of CVD in young people, and we provide recommendations for further research.
{"title":"Prevention of obesity and cardiovascular disease in young people using technology","authors":"S. Partridge, J. Redfern","doi":"10.17554/J.ISSN.2309-6861.2018.05.142","DOIUrl":"https://doi.org/10.17554/J.ISSN.2309-6861.2018.05.142","url":null,"abstract":"Cardiovascular disease (CVD) is the leading cause of death worldwide. Excess weight gain during adolescence (14-18 years) and young adulthood (18-24 years) is associated with CVD in later life. Despite the significant investment into treatment for obesity, efforts have had limited success. Aiming to prevent obesity by halting weight gains at critical life stages where weight gain occurs, such as adolescence and young adulthood, could be a solution towards combating the obesity epidemic and thus reducing CVD prevalence in later life. Technology-based interventions can improve lifestyle behaviours in adults. Currently, over 80% of young people in developed countries own a Smartphone. Smartphones may offer an opportunity for intervention. However, there is limited long-term evidence for the role of mhealth in primary prevention of CVD in young people. In this manuscript, we discuss and review the potential use of mhealth for the primary prevention of CVD in young people, and we provide recommendations for further research.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"57 1","pages":"718-722"},"PeriodicalIF":0.0,"publicationDate":"2018-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77850985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-03-18DOI: 10.17554/j.issn.2309-6861.2018.05.149
A. Berezin
Heart failure (HF) is a major factor contributing to premature death in patients with established cardiovascular (CV) disease. There is a large body of evidence that biological markers presumably natriuretic peptides, galectin-3, soluble ST2 and cardiac troponins could be the best tool for prediction of poor clinical outcomes in general population as well as in individuals with suspected or established CV diseases including HF. However, recent clinical trials have shown that abilities of these biomarkers regarding identification of morbidity and mortality risks distinguished in wide range and depended on numerous factors, i.e. age, sex, comorbidities, treatment regime and phenotypes of HF. Additionally, not all of these biomarkers except natriuretic peptides were best fitted to guided therapy of HF and consequently serial measures of them did not warrant improving of predictive value in follow-up especially in patients with preserved left ventricular ejection fraction. Growth-differentiation factor-15 (GDF-15) belongs to the transforming growth factor-β superfamily that regulates mitochondrial function of wide range of cells that involve in inflammation, oxidative stress, apoptosis, immune reaction, fibrosis, reparation and malignancy. This editorial is depicted the possibilities to extrapolate the predictive capabilities of GDF-15 from metabolic and tumor diseases to CV diseases including HF.
{"title":"Growth Differentiation Factor 15 As Promising Biomarker Of Poor Prognosis In Heart Failure","authors":"A. Berezin","doi":"10.17554/j.issn.2309-6861.2018.05.149","DOIUrl":"https://doi.org/10.17554/j.issn.2309-6861.2018.05.149","url":null,"abstract":"Heart failure (HF) is a major factor contributing to premature death in patients with established cardiovascular (CV) disease. There is a large body of evidence that biological markers presumably natriuretic peptides, galectin-3, soluble ST2 and cardiac troponins could be the best tool for prediction of poor clinical outcomes in general population as well as in individuals with suspected or established CV diseases including HF. However, recent clinical trials have shown that abilities of these biomarkers regarding identification of morbidity and mortality risks distinguished in wide range and depended on numerous factors, i.e. age, sex, comorbidities, treatment regime and phenotypes of HF. Additionally, not all of these biomarkers except natriuretic peptides were best fitted to guided therapy of HF and consequently serial measures of them did not warrant improving of predictive value in follow-up especially in patients with preserved left ventricular ejection fraction. Growth-differentiation factor-15 (GDF-15) belongs to the transforming growth factor-β superfamily that regulates mitochondrial function of wide range of cells that involve in inflammation, oxidative stress, apoptosis, immune reaction, fibrosis, reparation and malignancy. This editorial is depicted the possibilities to extrapolate the predictive capabilities of GDF-15 from metabolic and tumor diseases to CV diseases including HF.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"25 1","pages":"713-717"},"PeriodicalIF":0.0,"publicationDate":"2018-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78294115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-02-07DOI: 10.17554/J.ISSN.2309-6861.2018.05.141
O. Giampietro, M. Masoni, E. Matteucci, Chiara Giampietro, S. Giordani, C. Consani, F. Negri
AIM: Dyslipidemia plays a crucial role in the development of cardiovascular diseases. A correct lifestyle behaviour based on a balanced diet and moderate physical exercise is the first-line approach, however drug treatment (chiefly statins and/or ezetimibe) may be often needed. Among dietary supplements, so-called "nutraceuticals" are nowadays continuously proposed and frequently employed. In this paper we report our experience with a nutraceutical product largely utilized in Italy (as well as in Mediterranean area) (ARMOLIPID PLUS), based on red yeast rice, berberine, policosanol and some antioxidants, for the treatment of dyslipidemic people. MATERIAL AND METHODS: In this open-label trial we treated with this nutraceutical 37 dyslipidemic nondiabetics and 15 dyslipidemic type 2 diabetics for 12 months, monitoring serum lipids, fasting glucose, glycated hemoglobin, blood pressure, and performing also anthropometric measurements including skinfold thickness. RESULTS: Both in dyslipidemic and diabetic patients we observed a great (about 80-100 mg/dL) parallel decrease of total- and non-HDL Cholesterol, not justified by LDL-Ch decrease (about 37 mg/dL). Furthermore, while body weight and body mass index were not affected significantly by treatment, suprailiac skinfolds (around 6 cm) and total skinfold sum (10 cm) were heavily reduced by the nutraceutical in both groups of patients. CONCLUSION: The present paper confirms that this nutraceutical, due to the synergistic complementary interaction between berberine and red yeast rice, is a reliable option for effective management of dyslipidemia in metabolic disorders with glucolipidic abnormalities.
{"title":"Clinical Efficacy of A Nutraceutical Approach for the Management of Dyslipidemia in Metabolic Disorders: A One-Year Treatment With Armolipid Plus","authors":"O. Giampietro, M. Masoni, E. Matteucci, Chiara Giampietro, S. Giordani, C. Consani, F. Negri","doi":"10.17554/J.ISSN.2309-6861.2018.05.141","DOIUrl":"https://doi.org/10.17554/J.ISSN.2309-6861.2018.05.141","url":null,"abstract":"AIM: Dyslipidemia plays a crucial role in the development of cardiovascular diseases. A correct lifestyle behaviour based on a balanced diet and moderate physical exercise is the first-line approach, however drug treatment (chiefly statins and/or ezetimibe) may be often needed. Among dietary supplements, so-called \"nutraceuticals\" are nowadays continuously proposed and frequently employed. In this paper we report our experience with a nutraceutical product largely utilized in Italy (as well as in Mediterranean area) (ARMOLIPID PLUS), based on red yeast rice, berberine, policosanol and some antioxidants, for the treatment of dyslipidemic people. MATERIAL AND METHODS: In this open-label trial we treated with this nutraceutical 37 dyslipidemic nondiabetics and 15 dyslipidemic type 2 diabetics for 12 months, monitoring serum lipids, fasting glucose, glycated hemoglobin, blood pressure, and performing also anthropometric measurements including skinfold thickness. RESULTS: Both in dyslipidemic and diabetic patients we observed a great (about 80-100 mg/dL) parallel decrease of total- and non-HDL Cholesterol, not justified by LDL-Ch decrease (about 37 mg/dL). Furthermore, while body weight and body mass index were not affected significantly by treatment, suprailiac skinfolds (around 6 cm) and total skinfold sum (10 cm) were heavily reduced by the nutraceutical in both groups of patients. CONCLUSION: The present paper confirms that this nutraceutical, due to the synergistic complementary interaction between berberine and red yeast rice, is a reliable option for effective management of dyslipidemia in metabolic disorders with glucolipidic abnormalities.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"1 1","pages":"701-706"},"PeriodicalIF":0.0,"publicationDate":"2018-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86457533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-02-02DOI: 10.17554/j.issn.2309-6861.2018.05.139
A. Wilczynska, Ram B. Singh, J. Fedacko, S. Singhal
This study was conduc4ed to validate the questionnaire for assessment of type A behaviour and to determine its relation with socioeconomic status and coronary artery disease(CAD) in a randomly selected urban population. We studied 1806 subjects (904 men and 902 women) aged 25-64 years. The survey instruments were questionnaire: modified from existing questionnaires (Likeret scale, Jenkins activity survey and Friedman and Rosenman structured interview questionnaires). The questionnaire for assessment of type A behaviour was administered by a psychologist and subjects were divided into type A behaviour (n=306), possible type A behaviour (n=157) or no such behaviour (n=1343) according to rating of their type A behaviour based on scores of various attributes such as hostility, aggressiveness, ambitiousness, competitiveness and pace or time urgency. The prevalence of type A behaviour was significantly greater among men compared to women (21.9 vs 11.9%, p<0.01). The overall prevalence of type A and possible type A behavior was also significantly higher in men than women (32.4 vs 18.8%, p<0.01) and the overall prevalence of total behaviour abnormality was 25.6% in both sexes. Type A behaviour was highly prevalent among social class 1 and 2 subjects in both sexes and showed significant association with CAD. The findings indicate that type A behaviour assessed by scores constructed based on various attributes of behaviour is accurate and the personality rating scale validated by us may be used successfully in other population groups of India.
本研究旨在验证A型行为评估问卷的有效性，并确定其与社会经济地位和冠状动脉疾病(CAD)的关系。我们研究了1806名受试者(904名男性和902名女性)，年龄在25-64岁之间。调查工具为问卷:根据现有问卷(Likeret量表、Jenkins活动问卷和Friedman和Rosenman结构化访谈问卷)进行修改。A型行为评估问卷由一名心理学家进行，根据他们的A型行为的各种属性，如敌意、侵略性、野心、竞争力和速度或时间紧迫性的得分，受试者被分为A型行为(n=306)、可能的A型行为(n=157)或没有A型行为(n=1343)。A型行为在男性中的患病率明显高于女性(21.9% vs 11.9%， p<0.01)。男性A型及可能A型行为的总体患病率明显高于女性(32.4 vs 18.8%， p<0.01)，两性总行为异常的总体患病率为25.6%。A型行为在社会1级和社会2级受试者中普遍存在，且与CAD有显著相关性。研究结果表明，基于行为的各种属性构建的分数评估A型行为是准确的，我们验证的人格评定量表可能在印度其他人群中成功使用。
{"title":"Validation Of Type A Behaviour Questionnaire In Relation To Social Class And Coronary Artery Disease : The Indian Rating Scale For Type A Behaviour","authors":"A. Wilczynska, Ram B. Singh, J. Fedacko, S. Singhal","doi":"10.17554/j.issn.2309-6861.2018.05.139","DOIUrl":"https://doi.org/10.17554/j.issn.2309-6861.2018.05.139","url":null,"abstract":"This study was conduc4ed to validate the questionnaire for assessment of type A behaviour and to determine its relation with socioeconomic status and coronary artery disease(CAD) in a randomly selected urban population. We studied 1806 subjects (904 men and 902 women) aged 25-64 years. The survey instruments were questionnaire: modified from existing questionnaires (Likeret scale, Jenkins activity survey and Friedman and Rosenman structured interview questionnaires). The questionnaire for assessment of type A behaviour was administered by a psychologist and subjects were divided into type A behaviour (n=306), possible type A behaviour (n=157) or no such behaviour (n=1343) according to rating of their type A behaviour based on scores of various attributes such as hostility, aggressiveness, ambitiousness, competitiveness and pace or time urgency. The prevalence of type A behaviour was significantly greater among men compared to women (21.9 vs 11.9%, p<0.01). The overall prevalence of type A and possible type A behavior was also significantly higher in men than women (32.4 vs 18.8%, p<0.01) and the overall prevalence of total behaviour abnormality was 25.6% in both sexes. Type A behaviour was highly prevalent among social class 1 and 2 subjects in both sexes and showed significant association with CAD. The findings indicate that type A behaviour assessed by scores constructed based on various attributes of behaviour is accurate and the personality rating scale validated by us may be used successfully in other population groups of India.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"os-44 1","pages":"707-712"},"PeriodicalIF":0.0,"publicationDate":"2018-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87236918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-15DOI: 10.17554/J.ISSN.2309-6861.2018.05.138
Priscila Cristina Silva, R. S. Faria, Adriano Gonçalves Sallum, L. V. D. A. Sousa, V. Valenti, Paulo José Oliveira Cortez
Objective: This work focus is analysis of the physical and calibration conditions of the sphygmomanometers used at the Itajuba school hospital. Method: A quantitative, observational, cross-sectional study was performed with data collection of all aneroid and mercury sphygmomanometers from the institution, excluding those that were not in use or not belonging to the School Hospital. The analyzed variables were: Identification, Gauge, Clamp, Pear, Deflation valve, Air exhaust, Measured pressure measurements and Calibration. Results: Of the final sample of 76 sphygmomanometers, were unbalanced 76 sphygmomanometers, of which 56 (73, 7%) were of the aneroid type, 12 (15.8%) of the wall, 6 (7.9%) of the mobile column and 2 (2.6%) of mercury column, of the marks was predominant sphygmomanometers of the mark 1 , With 30 (41.7%). Most of the analyzed sphygmomanometers had a serial number of 98.7% and a number of Inmetro 75%. A clamp-type relationship with calibration prevalence was found, with velcro clamps being 6 times more likely to be calibrated than clamp-type. Conclusion: The analysis was satisfactory in relation to the quality, calibration and general state of the apparatus, with new analyzes necessary for other variable variables to obtain a good blood pressure measurement.
{"title":"Analysis of Mercury Sphygmomanometers in A Hospital School Analysis of Mercury Sphygmomanometers","authors":"Priscila Cristina Silva, R. S. Faria, Adriano Gonçalves Sallum, L. V. D. A. Sousa, V. Valenti, Paulo José Oliveira Cortez","doi":"10.17554/J.ISSN.2309-6861.2018.05.138","DOIUrl":"https://doi.org/10.17554/J.ISSN.2309-6861.2018.05.138","url":null,"abstract":"Objective: This work focus is analysis of the physical and calibration conditions of the sphygmomanometers used at the Itajuba school hospital. Method: A quantitative, observational, cross-sectional study was performed with data collection of all aneroid and mercury sphygmomanometers from the institution, excluding those that were not in use or not belonging to the School Hospital. The analyzed variables were: Identification, Gauge, Clamp, Pear, Deflation valve, Air exhaust, Measured pressure measurements and Calibration. Results: Of the final sample of 76 sphygmomanometers, were unbalanced 76 sphygmomanometers, of which 56 (73, 7%) were of the aneroid type, 12 (15.8%) of the wall, 6 (7.9%) of the mobile column and 2 (2.6%) of mercury column, of the marks was predominant sphygmomanometers of the mark 1 , With 30 (41.7%). Most of the analyzed sphygmomanometers had a serial number of 98.7% and a number of Inmetro 75%. A clamp-type relationship with calibration prevalence was found, with velcro clamps being 6 times more likely to be calibrated than clamp-type. Conclusion: The analysis was satisfactory in relation to the quality, calibration and general state of the apparatus, with new analyzes necessary for other variable variables to obtain a good blood pressure measurement.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"171 1","pages":"697-700"},"PeriodicalIF":0.0,"publicationDate":"2018-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79454345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：